Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives $39.81 Average PT from Analysts

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has received a consensus rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $39.81.

TNDM has been the topic of several research reports. Wells Fargo & Company decreased their price target on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 1st. Robert W. Baird cut their price target on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a “neutral” rating for the company in a research report on Thursday, May 1st. Mizuho began coverage on Tandem Diabetes Care in a report on Thursday, April 10th. They issued a “neutral” rating and a $20.00 price objective on the stock. Piper Sandler dropped their target price on Tandem Diabetes Care from $36.00 to $30.00 and set an “overweight” rating for the company in a report on Thursday, May 1st. Finally, Morgan Stanley cut Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $45.00 to $22.00 in a research note on Wednesday, March 5th.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM opened at $22.98 on Tuesday. The company’s fifty day moving average price is $18.66 and its 200-day moving average price is $28.16. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -11.91 and a beta of 1.47. Tandem Diabetes Care has a one year low of $15.75 and a one year high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. During the same period in the prior year, the company earned ($0.65) EPS. The firm’s revenue was up 22.3% compared to the same quarter last year. On average, equities research analysts anticipate that Tandem Diabetes Care will post -1.68 earnings per share for the current fiscal year.

Insider Transactions at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was acquired at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the acquisition, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. AlphaQuest LLC increased its stake in shares of Tandem Diabetes Care by 138.7% during the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 541 shares in the last quarter. Assetmark Inc. boosted its holdings in Tandem Diabetes Care by 42.9% in the first quarter. Assetmark Inc. now owns 1,750 shares of the medical device company’s stock worth $34,000 after acquiring an additional 525 shares in the last quarter. NBC Securities Inc. purchased a new stake in shares of Tandem Diabetes Care in the first quarter worth $37,000. Jones Financial Companies Lllp increased its holdings in shares of Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock valued at $41,000 after acquiring an additional 748 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in shares of Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock worth $65,000 after purchasing an additional 1,101 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.